SpringWorks lands FDA approval for nerve tumor treatment
SpringWorks Therapeutics, a biotech potentially on the verge of being acquired, won its second FDA approval. The agency on Tuesday gave the green light to Gomekli, a treatment for adults and ...
View ArticleNew CMO Dietmar Berger highlights Gilead’s ‘unique situation’ and its HIV...
Dietmar Berger said Gilead is in a “unique situation” as he assumes the role of chief medical officer, touting a “well-diversified" pipeline, potential launches and an eight-year stretch of no major...
View ArticleBiogen gets $250M in Royalty Pharma deal for lupus program
Biogen is turning to Royalty Pharma for some cash in exchange for rights to a lupus program, the companies announced Wednesday. The two have agreed on a deal for litifilimab, an anti-BDCA2 drug...
View ArticleExclusive: Longevity startup targets renegade proteins linked to diabetes and...
The human genome is chock-full of middle managers. Roughly 2,000 proteins, accounting for one-tenth of our genes, control how the rest of our genes are turned on or off. Normally these ...
View ArticleAfter passing on M&A offers, Abcuro raises $200M in bid to become commercial...
After quickly enrolling its pivotal trial and recruiting more patients with a rare muscle disease than anticipated, Abcuro went to its board to explore a $60 million to $80 million fundraise. That...
View ArticleCerula Care raises $3.7M to support cancer patients’ mental health
Cerula Care has raised $3.7 million in seed funding to help patients better fight cancer by checking in on them, supporting their mental health and helping with practical needs such as nudges to take...
View ArticleBiogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet
Plus, news about Odyssey Therapeutics, GSK, Aligos Therapeutics, Terrain Biosciences, the Gates Foundation and Neuphoria Therapeutics: Biogen appears to back away from dealmaking projections: The...
View ArticleAbbVie pens another T cell engager deal, this time with Xilio
AbbVie and Xilio Therapeutics are partnering to make “masked” T cell engagers, which they hope will be safer than currently available options. Xilio said Wednesday the collaboration would develop new...
View ArticleAnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis
AnaptysBio trumpeted a Phase 2b success in rheumatoid arthritis Wednesday morning after a similar program from Eli Lilly was discontinued late last year. Anaptys’ program, known as rosnilimab, hit its...
View ArticlePfizer wins approval in new indication for blood cancer drug Adcetris
Pfizer secured an eighth indication for its blood cancer drug Adcetris after the FDA approved its use in adults, in combination with two other medications, to treat relapsed or refractory large B cell...
View ArticleWhat CVS is doing about high medical costs
CVS Health ended 2024 as it started, with high medical costs in the company’s insurance business chipping away at its bottom line. The healthcare giant late last year tapped new CEO David Joyner to...
View ArticleKaiser Permanente calls on FDA and Congress to firm up accelerated approval...
While FDA is implementing new accelerated approval reforms, Kaiser Permanente says the reforms do not go far enough. The health system, which owns an insurer, said the agency needs to work with...
View ArticleNIH’s funding cut plan poses challenges for researchers despite court halt
An NIH cap on indirect cost payments for grant recipients is casting a shroud of uncertainty for research universities despite a judge’s order to block it. A federal judge this week
View ArticleNovo's weight loss drug helps curb some drinking habits, small study shows
New research from the University of North Carolina-Chapel Hill found that Novo Nordisk’s weight loss drug may help people curb their alcohol consumption. Results from the small Phase 2 study
View ArticleEx-DeepMind scientist launches AI biotech Latent Labs with $50M
Simon Kohl turned an internship at Google DeepMind into a key role in building AlphaFold2, the Nobel Prize-winning AI model that predicts the structure of proteins. Now, Kohl is venturing out on his...
View ArticleRoche sends experimental CNS drugs to Newleos, a new biotech backed with $93.5M
Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, further demonstrating that the pharma-to-startup pipeline for CNS drugs is...
View ArticleHunger-suppressing biotech Aardvark raises $94M in IPO
Aardvark Therapeutics, a biotech looking to address hunger rather than appetite for metabolic diseases, will go public on Thursday with a $94 million debut on the Nasdaq. The San Diego-based biotech...
View ArticleSanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test
Sanofi has been hit with a $250 million impairment charge after an E. coli vaccine candidate it was developing with Johnson & Johnson failed to clear a Phase 3 study. An independent data monitoring...
View ArticleNeumora replaces CEO with ex-chief Berns after trial failure
In a surprise move Thursday, Neumora remade its executive team and brought back its former CEO, following last month's failure of the brain health biotech's first big clinical test. Paul Berns, who ...
View ArticleIdorsia’s Tryvio licensing negotiations collapse amid cash squeeze
Idorsia’s plan to hand over the global rights to its blood pressure drug Tryvio has ended in disappointment after a deal announced in November fell through. The Swiss drugmaker said Thursday ...
View Article